Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxyne Limited ( (AU:BXN) ) has issued an announcement.
Bioxyne Limited has issued 85.5 million unquoted performance rights under its employee incentive scheme, effective 24 December 2025. The substantial grant of performance rights, which will not be quoted on the ASX, signals an increased emphasis on equity-based remuneration to align employees’ and executives’ interests with shareholders, potentially leading to future dilution but aimed at supporting staff retention and performance as the company pursues its strategic objectives.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Average Trading Volume: 2,263,434
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$92.21M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.